Edward Carr - Dianthus Therapeutics Chief Officer
| DNTH Stock | 20.27 0.50 2.41% |
Executive
Edward Carr is Chief Officer of Dianthus Therapeutics
| Age | 55 |
| Address | 7 Times Square, New York, NY, United States, 10036 |
| Phone | 929 999 4055 |
| Web | https://dianthustx.com |
Edward Carr Latest Insider Activity
Tracking and analyzing the buying and selling activities of Edward Carr against Dianthus Therapeutics stock is an integral part of due diligence when investing in Dianthus Therapeutics. Edward Carr insider activity provides valuable insight into whether Dianthus Therapeutics is net buyers or sellers over its current business cycle. Note, Dianthus Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Dianthus Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Edward Carr over three months ago Acquisition by Edward Carr of 60000 shares of Dianthus Therapeutics at 21.77 subject to Rule 16b-3 | ||
Edward Carr over six months ago Acquisition by Edward Carr of 238000 shares of Abeona Therapeutics subject to Rule 16b-3 |
Dianthus Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.1896) % which means that it has lost $0.1896 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2599) %, meaning that it created substantial loss on money invested by shareholders. Dianthus Therapeutics' management efficiency ratios could be used to measure how well Dianthus Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.25. The current Return On Capital Employed is estimated to decrease to -0.3. As of now, Dianthus Therapeutics' Non Currrent Assets Other are increasing as compared to previous years. The Dianthus Therapeutics' current Other Assets is estimated to increase to about 146.1 K, while Total Assets are projected to decrease to under 112.5 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Gary Whale | Zura Bio Limited | 50 | |
| RN MBA | Transcode Therapeutics | N/A | |
| Linda Mahoney | Phio Pharmaceuticals Corp | N/A | |
| Daniel MD | Transcode Therapeutics | 72 | |
| Calais Pharm | Transcode Therapeutics | 65 | |
| Kimberly Davis | Zura Bio Limited | 56 | |
| MD FACC | ZyVersa Therapeutics | 74 | |
| Verender Badial | Zura Bio Limited | 52 | |
| David Brady | Zura Bio Limited | N/A | |
| Alan Freidman | Transcode Therapeutics | N/A | |
| Kiran MBBS | Zura Bio Limited | 51 | |
| Michael Howell | Zura Bio Limited | 47 | |
| Melda Oconnell | ZyVersa Therapeutics | N/A | |
| Theresa Lowry | Zura Bio Limited | 50 | |
| Gael Hedou | Sonnet Biotherapeutics Holdings | 52 | |
Management Performance
| Return On Equity | -0.26 | ||||
| Return On Asset | -0.19 |
Dianthus Therapeutics Leadership Team
Elected by the shareholders, the Dianthus Therapeutics' board of directors comprises two types of representatives: Dianthus Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Dianthus. The board's role is to monitor Dianthus Therapeutics' management team and ensure that shareholders' interests are well served. Dianthus Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Dianthus Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Edward Carr, Chief Officer | ||
| Kristina Maximenko, Chief Officer | ||
| MD MBA, Chief Officer | ||
| Marino MBA, CEO and Presidentident | ||
| Adam Esq, General Counsel | ||
| Jennifer Ruff, VP Affairs | ||
| Judson Taylor, Head Operations | ||
| Scott MBA, Head Operations | ||
| Jeffrey Stavenhagen, Chief Officer | ||
| Rashieda Gluck, Head Operations | ||
| Ryan Savitz, CFO Treasurer |
Dianthus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Dianthus Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.26 | ||||
| Return On Asset | -0.19 | ||||
| Operating Margin | (13.77) % | ||||
| Current Valuation | 333.92 M | ||||
| Shares Outstanding | 29.6 M | ||||
| Shares Owned By Insiders | 8.76 % | ||||
| Shares Owned By Institutions | 91.24 % | ||||
| Number Of Shares Shorted | 5.1 M | ||||
| Price To Book | 1.82 X | ||||
| Price To Sales | 114.56 X |
Currently Active Assets on Macroaxis
When determining whether Dianthus Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Dianthus Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Dianthus Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Dianthus Therapeutics Stock:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Dianthus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more detail on how to invest in Dianthus Stock please use our How to Invest in Dianthus Therapeutics guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dianthus Therapeutics. If investors know Dianthus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dianthus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 7.22 | Revenue Per Share 0.19 | Quarterly Revenue Growth 1.351 | Return On Assets (0.19) | Return On Equity (0.26) |
The market value of Dianthus Therapeutics is measured differently than its book value, which is the value of Dianthus that is recorded on the company's balance sheet. Investors also form their own opinion of Dianthus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Dianthus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dianthus Therapeutics' market value can be influenced by many factors that don't directly affect Dianthus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dianthus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dianthus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dianthus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.